unknown by unknown
line was determined during a 3-day continuous incubation. There were 
marked differences in sensitivity to each drug (RCC39, RCC42, RCC45 EC50 
for 5-FU  0.8, 3.4, 0.5 mM and for SN-38 240, 39, 17 ng/mL respectively). 
EC25 concentrations were derived from these model fits, and cells were then 
treated at these concentrations for 2 sequential 3-day periods, with: SN-38 
alone d1-6; 5-FU alone d1-6; SN-38 + 5-FU in combination d1-6; SN-38 d1-
3 followed by 5-FU d4-6; 5FU d1-3 followed by SN-38 d4-6.  The use of 
both drugs in combination, or 5-FU followed by SN-38, produced no better 
than additive effects in any cell line. However, in RCC39 and RCC42, the 
sequence of SN-38 followed by 5-FU showed marked synergy, with % 
viabilities on day 6 of only 20% and 17% respectively (p<0.01 for both cell 
lines, compared to the expected effect). Synergy was not found with RCC45. 
In RCC39 and RCC42, 5-FU exposure resulted in characteristic increases in 
TS protein by day 3, but this increase was not observed in either cell line 
when SN-38 was given prior to 5-FU.    
These data suggest that SN-38 and 5-FU may act synergistically in renal 
cancers, and that sequence is critical in this interaction. This effect may be 
mediated via TS.    
As both drugs show activity in this setting, these data support the 
investigation of this sequence in a clinical trial.  
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The anthraquinone conjugate of the unnatural amino acid (S)-
cyclohexylalanine, NU:UB 199, is a dual inhibitor of topoisomerase I and II 
enzymes with a novel pattern of inhibition. NU:UB 199 stimulated topo I-
induced DNA cleavage (44% nicked pBR322 plasmid) in vitro. In common 
with camptothecin, this conjugate also stabilises covalent topoisomerase I-
DNA cleavable complexes in intact cells and thus behaves as a topo I poison. 
The extent of immunoband depletion of topo I in human HL60 cells by 
NU:UB 199 at 100µM was comparable to that obtained with camptothecin at 
50µM when applied to the incubation medium for 45 minutes. Additionally, 
the conjugate is a catalytic inhibitor of topo II; inhibition of topo II-mediated 
relaxation of pBR322 plasmid DNA in vitro is complete at 1µM. In HL60 
cells, immunoband depletion (complete at 200M) of topo II, but not the -
isoform, was observed, suggesting preferential targeting of the -isoform. 
NU:UB 199 is active in the low µM range across the NCI 60-cell line panel 
and shows exceptional selectivity for the cell lines of the colon sub-panel. 
Furthermore, this conjugate is active in the MAC15A murine 
adenocarcinoma tumour model that is refractory to standard agents. The pre-
clinical data indicates that NU:UB199 is a promising new anti-tumour agent 
that targets both topo I and topo II and does not suffer from the problems of 
structural lability and short-lived drug-stabilised DNA-topo cleavable 
complexes normally associated with the camptothecins.  
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The refractive nature of hypoxic tumour cells to most forms of cancer 
therapeutics makes this population an attractive target for anti-cancer drug 
design. We are currently developing indolequinones as bioreductive drugs for 
use in cancer chemotherapy. These compounds require enzymatic reduction 
to yield the cytotoxic moiety. However, the expression of the one- and two- 
electron reducing enzymes required for drug activation is heterogeneous in 
human malignancies. To overcome the potential variability in reductive-
activation we aim to exploit specific enzyme: bioreductive drug combinations 
in an enzyme – directed gene therapy approach. We have investigated the 
role of two key reducing enzymes, DT-diaphorase (DTD; two-electron) and 
cytochrome c P450 reductase (P450R; one electron) in the cytotoxicity of the 
prototype bioreductive drug, mitomycin C (MMC). Stable cell lines were 
generated from three breast carcinoma cell lines (T47D, MDA 231 and MDA 
468) to overexpress either DTD or P450R. The level of enzyme activity 
achieved varied between 200-1000 fold increase in activity compared to 
wild-type cells for DTD and 20-60 fold increase for P450R. Both DTD and 
P450R overexpression sensitised cells to MMC in aerobic conditions. The 
most profound effect was seen in the MDA 468 cells, where the IC50 value 
for MMC was reduced 27-fold by DTD over-expression. P450R over-
expression yielded a five-fold reduction in IC50 in this cell line. No specific 
increase in cytotoxicity was seen when the clones were exposed to drug 
under anoxic conditions. To analyse whether this sensitisation was 
maintained  in vivo, MDA468 wildtype cells and the DTD and P450R over-
expressing clones were established as xenografts in nude mice. The fold-
increase in enzyme activity in the DTD and P450R clones relative to 
wildtype was maintained, but the absolute levels of activity were markedly 
reduced in all tumour types compared to that seen in vitro. In keeping with 
our  in vitro findings, the MMC sensitisation achieved by DTD over-
expression was greater than that by P450R over-expression in vivo, with T/C 
(treated tumour volume/control tumour volume x 100) of 18% for DTD and 
61% for P450R at the time of removal of the first control tumour. We now 
aim to evaluate adenoviral delivery of DTD and P450R as a means of 
sensitising established human xenografts to MMC, against which we can 
compare the efficacy of our novel indolequinone drugs in future studies. 
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Introduction: For most gene therapy approaches to cancer it is crucial to 
transfect the therapeutic gene into most if not all the transformed cells. 
Although different types of bystander effects provide some leverage in 
improving the efficacy of treatments the specific, efficient, and safe delivery 
of the therapeutic gene remains an obstacle which hampers the progress of 
these novel therapies into the clinic
1. 
Polyethylenimine (PEI) polymers have proven versatile and efficient 
synthetic gene delivery systems, but despite its efficacy PEI has some 
disadvantages, namely the bias of biodistribution to the lung and its 
significant toxicity in vitro and in vivo.  
Using a modular modification strategy we have created a vesicle/polymer 
hybrid system with improved performance and safety profile, particular in 
vivo.  
Methods:  4 PEI variants were produced: namely palmitoyl-PEI (P-PEI), 
palmitoyl-polyethylene glycol-PEI (PP-PEI), quaternary ammonium-PEI (Q-
PEI), and quaternary ammonium palmitoyl-PEI (QP-PEI). The chemistry and 
physicochemistry of the polymers and the derivatives were characterised 
(elemental analysis, 1H-, 13C- NMR, dynamic and static light scattering, 
electron microscopy, zeta potential). The biological testing involved assays of 
cytotoxicity (MTT), serum/plasma interaction, haemolysis, and erythrocyte 
aggregation. Efficiency of transgene expression was assessed using b-
galactosidase (in vitro) or GFP (in vivo, mouse model) using 
immunohistochemistry. 
Results:  Changes of key physicochemical properties such as charge, nitrogen 
density, and self-aggregation were linked to the biological properties of these 
systems. All polymers condensed DNA at a polymer, DNA weight ratio of 
2.5: 1 or less. The haemolytic activity of the polymers was very low and all 
of the modified polymers proofed to be less cytotoxic than the parent 
polymer. Although the parent polymer PEI was superior to the modified 
polymers as a transfection agent in vitro the hybrid systems were superior in 
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followed the trend QP-PEI > P-PEI > PEI > Q-PEI. 
Conclusion: Polymer/vesicle hybrid type gene delivery systems maybe used 
to combine and exploit the complementary qualities of both, lipoplexes and 
polyplexes, in one system. It is known that good gene expression in vitro 
does not in anyway predict good expression levels in vivo. Here we 
demonstrate that the opposite is also true, i.e. the lack of expression in vitro 
does not predict for lack of expression in vivo.  
References  Schätzlein AG. Non-viral vectors in cancer gene therapy: 
principles and progress. Anti-cancer Drugs 2001; 12: 275-304. 
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Background: While particulate drug carriers such as liposomes have proven 
to be clinically useful in various cancers  targeted delivery of drugs to solid 
tumours remains a considerable challenge.  The main barriers experienced 
when targeting to the tumour are closely related to the interplay between 
tumour growth and tumour vascularisation. Tumour induced blood vessels 
(neovascularisation) have a leaky architecture which, in combination with 
compression of surrounding tissue, leads to an increased interstitial pressure 
and changes the flow of biological fluids with in the tumour mass. This limits 
convective, size-independent transport, and distribution of molecules and 
carriers throughout the tumour rather depends on  diffusion, with the flux 
correlating inversely with the molecular weight of the drug/carrier.  To 
address this problem we have developed low molecular weight conjugates (< 
3kD), so called nanoconjugates, of a small drug or toxin and a targeting 
ligand coupled through a (cleavable) linker group. Nanoconjugates offer 
potential advantages for tumour specific delivery in diffusion-limited 
situations.  
Method: Phage display was used to identify small peptides that target the 
transferrin receptor (TfR), which is frequently overexpressed in tumours. A 
library of phage expressing a cyclic nona-peptide was panned against TfR. 
The panning procedure was monitored using eluted phage counts and surface 
plasmon resonance. Another ligand tested was based on cyclic integrin 
binding peptides targeting the V3 integrins. Various conjugates of the 
targeting peptides carrying fluorescent probes or a model drug, doxorubicin, 
were prepared, purified and characterised. Some of the doxorubicin 
conjugates were prepared using a intracellular cleavable peptide linker 
between targeting moiety and drug. Biological properties were tested using 
MTT cytotoxicity assays, flow cytometry and confocal microscopy.  
Results: In the panning process a peptide ligand, which mediated a 30-50-
fold increased receptor specific cellular uptake of the phage, was identified. 
The ligand targeted nanoconjugates–in contrast to the free drug–are being 
taken up by receptor mediated endocytosis. This appeared to be specific 
(TfR) as it could be inhibited with excess substrate. Uptake was increased in 
receptor positive cell lines after 2h incubation, but this advantage was lost 
after longer exposure (V3). Cytotoxicity was significantly lower that that 
of free drug (Dox) with and with our the cleavable linker. Experiments to 
determine whether these targeted nanoconjugates may be useful for the 
targeting of tumours in vivo are on-going. 
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The issue of gene delivery has recently been identified as the bottleneck for 
human gene therapy in general [1]. For cancer gene therapy it is namely the 
lack of transfection efficiency and specificity, of synthetic gene delivery 
agents which hamper transfer of new therapeutic strategies into the clinic [2]. 
Viral vectors, while more efficient, have raised serious safety concerns. 
While numerous compounds have been tested as potential delivery agents 
this approach was historically based on trial and error. Rational design of 
molecules which show optimum interaction with DNA would greatly 
accelerate the development of more efficient systems. 
The use of dendrimers as gene delivery agents has been largely focused on 
the use of the polyamidoamine molecules and although polypropylenimine 
dendrimers contain 100% protonable nitrogen and bind DNA they have been 
relatively poorly studied as gene transfer agents. Here we demonstrate how 
insights from computer based molecular modelling can be used to select 
suitable molecules from a series of polypropylenimine dendrimers.  
Methods:  DNA binding was evaluated by measuring the reduced 
fluorescence of ethidium bromide and molecular modelling of dendrimer – 
DNA complexes was also carried out. Cell cytotoxicity was evaluated against 
the A431 cell line using the MTT assay. In vitro transfection was evaluated 
against the A431 cell line using the -galactosidase reporter gene and 
DOTAP, served as a positive control. 
Results: Molecular modelling revealed that the number of dendrimer – DNA 
contact points per dendrimer and the simulated dendrimer - DNA 
intermolecular energies increase with dendrimer generation. DNA 
condensation (measured by the exclusion of ethidium bromide), and 
experimentally determined dendrimer - DNA positive zeta potential also 
increased with dendrimer generation. Cell cytotoxicity was largely but not 
exclusively generation dependant and cytotoxicity followed the trend DAB 
64 > DAB 32 > DAB 16 > DOTAP > DAB 4 > DAB 8 while transfection 
efficacy followed the trend DAB 8 = DOTAP = DAB 16 > DAB 4 > DAB 32 
= DAB 64.  
Conclusion  The generation 2 polypropylenimine dendrimer combines a 
sufficient level of DNA binding with a low level of cell cytotoxicity to give it 
optimum gene transfer activity in vitro. 
1. Anderson WF. Human gene therapy. Nature 1998; 392: 25-30. 
2. Schätzlein AG. Non-viral vectors in cancer gene therapy: Principles and 
progress. Anti-cancer Drugs 2001; 12: 275-304.  
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Introduction and Objectives: A novel gene therapy system has been 
developed using adenoviruses encoding E. Coli nitroreductase (NR), which 
converts the prodrug CB1954 into a potent alkylating agent. To elicit 
additional systemic antitumour effects single and combination adenoviral 
vectors expressing NR and mouse granulocyte-monocyte colony stimulating 
factor (mGMCSF) have also been generated. The syngeneic TRansgenic 
Adenocarcinoma Mouse Prostate (TRAMP) model of prostate cancer was 
utilised both in vitro and in vivo to characterise the effects of these vectors in 
prostate cancer. Methods: UV microscopy and FACS analysis were used to 
assay infectivity of the cell lines by adenoviruses in vitro with a vector 
expressing the marker gene Green Fluorescent Protein (GFP). A -
galactosidase expressing vector was used to assay infectivity and transgene 
expression levels in vivo. Subcutaneous flank tumours were established in 
syngeneic C57/Bl6 mice for in vivo studies of both intratumoural injection 
and ex-vivo gene therapy. Results: Approximately 100% of TRAMP cells 
were infected at an adenoviral multiplicity of infection (MOI) of 100. In vitro 
enhancement of toxicity to CB1954 was similar in cells infected with the dual 
virus or a virus expressing NR on its own. Studies of established 
subcutaneous TRAMP C2 tumours injected with Ad5--Galactosidase 
showed 1000 fold increases in transgene expression compared with mock 
infections. Injection of the dual expressing vector Ad5-mGMCSF-NR 
produced a survival benefit in animals with TRAMP C2 tumours, but no 
additional benefit in survival was produced by injection of CB1954. Ex-vivo 
gene therapy of TRAMP C2 cells with Ad5-mGMCSF ablated tumour 
development compared with control adenovirus. Conclusions: Efficient 
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has been shown in the TRAMP model. Subcutaneous tumours grown in 
syngeneic mice respond to intratumoural Ad5-mGMCSF/NR but addition of 
prodrug conferred no additional survival advantage. Ex-vivo treatment of 
TRAMP C2 cells with Ad5-mGMCSF ablates tumourigenesis, suggesting 
that mGMCSF is the therapeutically active transgene.  
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Introduction and Objectives: An adenovirus dl1520, which selectively 
replicates in & kills cancer cells, is produced by deletion of the adenoviral 
E1B sequence. Variants of dl1520 containing the gene for the prodrug-
converting enzyme E. Coli nitroreductase (NR) were generated in an attempt 
to enhance cancer cell killing. The transgene is placed under the control of a 
prostate specific transcriptional regulatory region. Methods: The gene for 
NR was cloned downstream from a 632bp PSA promoter sequence and a 
single 1469bp PSA enhancer sequence into the E1 region of the adenoviral 
genome. Replication of the virus was analysed by dot blotting of viral DNA 
preparations. LNCaP cells were infected with a similar marker virus encoding 
GFP and transgene expression analysed by UV microscopy and FACS 
analysis. NR expression was analysed by Western blotting of protein lysates 
of LNCaP cells infected with adenovirus encoding NR Results: Replication 
of the adenoviral vector within LNCaP cells was demonstrated on dot blot 
analysis of viral DNA preparations. Infection of LNCaP cells with virus 
encoding GFP demonstrated high levels of transgene expression by both UV 
microscopy and FACS analysis. Western blot analysis confirmed rising NR 
expression levels over a 5-day time course. Infection of LNCaP cells with NR 
encoding adenovirus and addition of the prodrug CB1954 produced additive 
cell killing. Conclusions: Novel adenoviruses capable of replicating and 
expressing marker and therapeutic transgenes in the prostate cancer cell line 
LNCaP have been produced. Transgene expression levels from the PSA TRR 
can be increased by viral replication. Additive cell killing effects have been 
achieved using this vector in its capacity as gene therapy vector and viral 
oncolytic agent. 
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Three-and four-stranded DNA structures are important targets in drug design.  
Antigene strategies for protein down-regulation require adjuvant ligands to 
stabilise triplex structures; four-stranded DNA is implicated in c-myc 
expression and the abnormal genomic DNA of Werner’s, Bloom’s and 
Fragile-X syndromes, besides its role in the regulation of telomerase.   
Ligands with precisely-defined structural selectivity could therefore have a 
range of potential therapeutic applications.  Furthermore, the avoidance of 
undesirable cytotoxic effects dictates that any competing affinity for duplex 
structures must be eliminated in the course of the design. 
Pyrimidines bearing (
-aminoalkyl)aryl substituents (e.g. 1) are intriguing 
ligands for high-order DNA structures.  Preliminary studies
1 indicate that 
thioether-linked compounds are remarkable stabilisers of triplex DNA, whilst 
minor alteration of the functional groups in the linker switches the structural 
preference toward four-stranded DNA structures. 
 
 
 
 
 
  N  N 
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1 
Novel 4,6-diarylpyrimidines and related chromophores have been designed 
and synthesised to explore how the linker functional groups and length, the 
disposition of charges and amine pKa influence the SAR for interaction with 
relevant nucleic acid secondary structures.  Details of the synthesis, 
biophysical studies and in vitro cytotoxicity will be presented. 
(1) Wheelhouse et al., 2001, Clin, Cancer Res. 7 711 Suppl. S.   Murphy et 
al., 2001, Br. J. Cancer 85 S1 92. 
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Many tumour cell lines develop resistance towards alkylating 
chemotherapeutic agents due to the active status of the DNA repair protein 
O6-alkylguanine-DNA alkyltransferase (ATase).  This protein recognises and 
repairs the alkylated lesions formed at the O6 position of guanine bases in 
DNA, through which the cytotoxic effect would otherwise be derived.   
Hitherto, ATase inhibitors have been designed to covalently modify the 
active site of the protein, e.g. benzylguanine. Herein we present the design, 
synthesis and preliminary evaluation of a different kind of substrate analogue 
that may interact non-covalently with the ATase protein. 
Careful examination of X-ray crystal structures of the active site of the 
human form of the repair protein – in its native form and covalently modified 
by known inactivators of the protein – coupled with consideration of the 
reaction mechanism of the repair process has allowed the design of guanine 
derivatives which might bind in the active site by electrostatic and hydrogen 
bonding interactions.  Furthermore, these novel derivatives bear acidic or 
basic functional groups which might interfere with catalysis of the DNA 
repair reaction.  Such substrate analogues may be useful probes for 
crystallographic studies of purine-protein complexes and have application to 
the potentiation of cytotoxic chemotherapy. 
Details of the design and synthesis of novel 6-substituted purines will be 
presented, accompanied by preliminary data on their ability to bind and 
inhibit the ATase protein. 
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Aims: We have developed a novel targeted radiotherapy/gene therapy 
strategy for treatment of malignant disease utilising introduction of the 
Noradrenaline transporter gene (NAT) into malignant cells. We introduced 
NAT into non-NAT expressing UVW glioma cells and endowed the cells 
with the ability to achieved high levels of  [1
31I]MIBG and [
211At]MABG 
uptake and dose-dependent cell kill. A requirement for cancer gene therapy, 
is tumour specific expression of therapeutic transgenes. We investigated 
potentially tumour specific promoters, (the human telomerase promoters 
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at levels sufficient for therapeutic effect following radionuclide 
administration. 
Methods: UVW cells were stably transfected with the NAT gene under the 
control of the RSV, hTERT or hTERC promoter elements.  Gene expression 
levels were determined by MIBG uptake. Cytotoxicity was assessed in 
multicellular tumour spheroids via clonogenic survival and regrowth delay 
after administration of [
211At]-astatinated benzylguanidine ([
211At]MABG) 
and [
131I]MIBG. 
Results and Conclusions: UVW cells transfected with RSV/NAT, 
hTERC/NAT and hTERT/NAT were endowed with the capacity for active 
uptake of [
131I]MIBG and [
211At]MABG. NAT gene expression via the 
hTERC and hTERT promoters resulted in uptake levels 70% and 60% of that 
achieved by the RSV promoter control.  We observed dose dependant cell kill 
of clonogens derived from [
131I]MIBG-treated spheroids. Reduction in   
surviving fraction was related to promoter activity. Administration of 
[
211At]MABG resulted in spheroid sterilisation at doses 1000 times lower 
than those required using [
131I]MIBG. All NAT transfected cells, regardless 
of the promoter employed, were sterilised by the same dosage of 
[
211At]MABG. These results indicate that the human telomerase promoters 
are excellent candidates for tumour-specific transgene expression and that 
NAT gene transfer in combination [
211At]MABG treatment is a potent anti-
cancer strategy. 
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CYP1B1 is a cytochrome P450 mono-oxygenase which is consistently over-
expressed in a range of human tumours (reviewed by GI Murray et al., Annu 
Rev Pharmacol Toxicol. 2001;41:297-316). As part of the target validation 
process CYP1B1 protein expression has been characterised in clinical head 
and neck squamous cell carcinomas (HNSCCs) and in a series of human 
tumour xenografts from low passage head and neck cancer cell lines. The 
latter to be evaluated as a clinical model to test a novel CYP1B1/prodrug 
combination designed to target the delivery of the radiosensitiser/cytotoxin 
nitric oxide to tumours.  
Immunhistochemistry was performed using a monoclonal antibody specific 
for CYP1B1 which did not react with other cytochrome P450s including 
CYP1A1 and CYP1A2 (McFadyen et al., J Histochem Cytochem. 
1999;47:1457-1464). HNSCCs taken from a range of anatomical sites were 
of variable grade (n = 23). The intensity of immunoreactivity was assessed on 
a semi-quantitative scale as strong (3+), moderate (2+), weak (1+), negative 
(-). The majority of tumours showed positive immunoreactivity for CYP1B1 
but both inter- and intra-patient variability in CYP1B1 protein expression 
was evident. Only three (13%) of tumours did not exhibit any 
immunoreactivity for CYP1B1, two tumours (9%) showed weak CYP1B1 
immunoreactivity, six (26%) tumours displayed moderate immunoreactivity 
while twelve (52%) showed strong CYP1B1 immunoreactivity. In each case 
CYP1B1 expression was localised in the cytoplasm of the tumour cells and 
was absent from the associated normal stromal tissue. Spectral image analysis 
technology developed at the Gray Cancer Institute, which exploits the 
characteristic absorptions of individual stains (to distinguish stained from 
non-stained areas or co-localisation of stains), was used to confirm tumour-
specific localization of CYP1B1. Similar patterns of expression have been 
observed previously in a range of malignancies and emphasizes the 
importance of CYP1B1 as a target for cancer therapeutics.    
Previously, the inability to identify suitable experimental tumour models, 
which constitutively express CYP1B1 (with the frequency and intensity 
observed in clinical tumours), has proven a hinderance to understanding the 
underlying mechanisms of CYP1B1 regulation. In this study human tumour 
xenografts from low passage head and neck cell lines (including the UT16A, 
UT24A, UT15, UT33) have been found to contain the CYP1B1 phenotype. 
The UT16A and UT24 xenografts in particular exhibited strong CYP1B1 
protein expression compared to many human tumour xenografts derived from 
established cell lines.  
In conclusion, HNSCC expresses the CYP1B1 protein with high frequency (n 
= 23, 90%). A suitable in vivo model for studying both CYP1B1 regulation 
and testing CYP1B1-activated cancer therapeutics has been identified.  
This work is supported by Cancer Research UK.  
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Introduction: 
New treatments are  needed for patients with hormone refractory prostate 
cancer. We have investigated its effectiveness of the CD/5-FC suicide gene 
therapy system in a rat prostate cancer model. 
Method: 
PA3 cells were stablely transfected with cytosine deaminase using a double-
copy recombinant retrovirus under the control of the ERBB2 promotor. 
Transfection was confirmed using immunohistochemistry.  
Cell cytotoxicity with 5-FC was assessed using the MTS assay. 
Apoptosis was assessed using the commercially available Apoptag kit. 
Bystander effect was assessed by plating cells at different concentrations of 
wild type and transfected cells.  Cell viability was assessed using the MTS 
assay. 
Results: 
Cytosine deaminase expression was confirmed by immunohistochemistry. 
Six days treatment with 10ug/ml 5-FC resulted in 40% cell death in the PCD 
cells compared to only 5% on the wild-type. 
Apoptosis was shown in  30% of  PCD cells compared to 0% in PA3-WT 
after 6 days treatment with 5-FC. 
Conclusions: 
In our studies cell death by apoptosis can be shown in transfected cells in 
vitro. We have shown a significant bystander effect in vitro and are currently 
using this system in an animal model. 
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CYTOSOLIC HUMAN NOS II ACTIVITY IN MDA 231 BREAST 
TUMOUR TRANSFECTED CELLS ENHANCES SR4233 
ACTIVATION AND TOXICITY.  
Edwin Chinje, Jian Feng, Sanjeev Paul Sharma, Natasha Wind, Rachel 
Cowen and Ian Stratford. Experimental Oncology Group, School of 
Pharmacy, University of Manchester, Oxford Road, Manchester, M13 9PL, 
UK. 
 
SR4233 (tirapazamine, TPZ) is a lead bioreductive drug currently in clinical 
trials. It is selectively toxic to hypoxic cells commonly found in solid 
tumours and toxicity results from the intracellular metabolism of the drug to a 
highly toxic radical under hypoxia. Nitric oxide synthase (NOS) is an 
endogenously up-regulated enzyme that could provide tumour selective 
metabolism of chemotherapeutic prodrugs. Significantly, elevated levels have 
been found in several neoplastic tissues. Its dimeric nature provides two 
distinct catalytic domains (a reductase and an oxygenase) that will bioactivate 
a broad repertoire of chemotherapeutic agents including TPZ. The enzyme is 
a haem-based protein similar to members of the cytochrome P450 family and 
the reductase domain shares a high degree of sequence homology with 
cytochrome P450 reductase (P450R). However, unlike the former two 
enzymes, NOS II (inducible NOS) is soluble and exclusively expressed 
within the cytoplasm. Since, some reports have suggested that only 
metabolism of TPZ in the nucleus is likely to contribute to DNA damage 
[Evans JW et al., 1998, Cancer Res. 58: 2098- 2101], we have exploited this 
differential cellular localization to evaluate the contributions of cytosolic 
metabolism of TPZ to its overall toxicity. To achieve this, we have 
constitutively over-expressed NOS II by employing an optimised expression 
vector in which the human elongation factor 1 promoter produces a 
bicistronic message containing the genes for human NOS II and puromycin 
resistance. Following successful transfection of the human breast cell line, 
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II activity.  
NOS reductase activity as measured by the NADPH-dependent reduction of 
cytochrome c ranged from 7.5–22.0 nmol cyt. c reduced/min/mg. The highest 
activity represented about 6-fold increase over parental activity. Similarly, 
the catalytic activity of the oxygenase domain, measured by the conversion of 
14C-labelled L-arginine to L-citrulline, ranged from 20–66 pmol citrulline / 
min/mg and the highest activity was about 110-fold over parental cell 
activity. NADPH-dependent metabolism of TPZ to the stable two-electron 
metabolite, SR4317, was determined by HPLC analysis. Rate of metabolism 
was enhanced by the increase in NOS II expression. In addition, direct 
detection of the TPZ radical formation by the dihydrorhodamine (DHR) 123 
assay, correlated with HPLC metabolism data (r
2 = 0.92). DT-diaphorase 
activity (can metabolise TPZ in a single 2-electron step by-passing the free 
radical) did not alter as a result of the clonal process.  Sensitivity to TPZ 
following 3 hr hypoxic exposure also increased with elevated NOS II levels. 
Taken collectively, our data shows that cytosolic NOS II may contribute 
significantly to the bioactivation of tirapazamine.   
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CHARACTERISATION AND QUANTIFICATION OF DNA 
ADDUCTS FORMED BY THE PLATINUM DRUG BBR 3464.   
TRL John
1, CJ Ottely
2, DG Pearson
2, MJ Tilby
1.   
1Cancer Research Unit, Medical School, University of Newcastle upon Tyne, 
NE2 4HH.  
2 Department of Geological Sciences, University of Durham, 
Science Laboratories, South Road, Durham, DH1 3LE. 
 
Background  The development of cisplatin resistance has seen the need for 
novel anti-cancer agents that can overcome this resistance.  BBR 3464 is the 
first trinuclear platinum drug to enter clinical trials.  It differs from cisplatin 
in its length and its +4 charge.  These differences are believed to enable BBR 
3464 to form adducts markedly different in structure to those formed by 
cisplatin 
Methods  Purified DNA was reacted with BBR 3464 or cisplatin to give an 
adduct frequency of 1 per kilobase.  DNA was also extracted from drug 
treated human ovarian A2780 cells.  Purified DNA was digested using 
nuclease P1 and DNase 1 and analysed by ionexchange chromatography with 
elution using NaCl concentration gradients.  BBR 3464-DNA was also 
digested with a higher concentration of the above enzymes (enhanced 
digestion).  Platinum content in fractions were analysed using inductively 
coupled plasma mass spectrometry (ICP-MS).  Purified DNA Samples were 
analysed using a sensitive competitive ELISA procedure (1) that detects low 
levels of adducts formed by cisplatin. 
Results  Analysis of cisplatin-DNA adducts using the Mono Q anion-
exchange column gave the expected pattern of platinum containing peaks (2).  
None of the BBR 3464 derived material from enhanced digestion was 
retained on this column.  Analysis using the Macro-prep CM column 
revealed two main peaks of BBR 3464 derived material that eluted at 6 
minutes (1.5M NaCl) and 10.5 minutes (2.6M NaCl).  BBR 3464 adducts 
showed markedly lower immunoreactivity than cisplatin adducts ( 2000 
fold).  Three to four times the levels of adducts were detected on extracted 
DNA treated with BBR 3464 as compared to cisplatin at equivalent drug 
doses. 
Conclusion  The chromatographic behaviour and immunological properties 
of DNA adducts formed by BBR 3464 indicate markedly different properties 
compared to cisplatin adducts.  The enhanced digestion needed for BBR 
3464-DNA samples may indicate that BBR 3464 is distorting the DNA and 
restricting access of digestive enzymes.  It is anticipated that the strong 
affinity of BBR 3464 adducts to the cation-exchange column will permit 
maximum sensitivity for quantification by ICP-MS of adducts in DNA from 
blood cells collected during a recent phase II trial.   
1.  Tilby et al 1991.  Cancer Research. 51: 123. 
2.  Fichtinger-Schepman et al 1985.  Biochemistry. 24: 707. 
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ORAL DNA VACCINATION FOR ERBB2-EXPRESSING MURINE 
MAMMARY TUMOUR USING ATTENUATED SALMONELLA 
TYPHIMURIUM . 
Michael A*, Dalgleish A, Pandha H- St. George’s Hospital Medical School, 
Oncology Dept. Cranmer Terrace Lonon SW17 ORF 
 
Attenuated salmonellae have been extensively studied as live vectors for 
delivery of heterologous antigens. They are safe, highly immunogenic and 
can elicit long-lasting protective systemic and mucosal immunity. Oral 
immunization with S. typhimurium harboring plasmid DNA has resulted in 
gene delivery to gut lymph nodes, and induction of immunity to antigens 
encoded by the plasmid. There are several types of Salmonella mutants 
currently used for gene delivery. The most common, harbour mutations in 
aromatic amino acids or purin biosynthesis pathway (e.g. aroA, aroC, aroD 
and purA, purE), deficient production of adenylate cyclase (cya) or cyclic 
AMP receptror protein (crp) or mutations affecting the global regulatory 
system (phoP/phoQ).  
We are evaluating two new S. thyphimurium mutants, SPI2-sifA and ssav, as 
gene therapy vectors. In vitro gene transfer experiments using the plasmid 
pIRES2, which contains the Green Fluorescent Protein (GFP) reporter gene 
cDNA under a eukaryotic promoter have been completed in mouse 
macrophages and human monocyte cell lines-J7742 and U937 respectively. 
The expression of GFP using fluorescent microscope, was detected in 2% of 
cells. The same protocol was applied to primary mouse macrophages  where 
expression of GFP was seen in up to 60% of cells.  
We plan to use SPI2 mutants as gene therapy vectors using an erbB2 DNA 
vaccine in mouse mammary tumour model. We have cloned truncated 
versions of the erbB2 genes representing peptide epitopes for the 
intracelleular and extracellualr domains of the erbB2 oncoprotein. We will 
use S. typhimurium to deliver these plasmid constructs as DNA vaccines by 
the intraperitoneal and oral routes, and compare the efficacy and 
immunogenicity of this approach with intramuscular delivery of the same 
constructs. 
All in vivo preclinical studies comply with UKCCR “ Guidelines for the 
Welfare of Animals in Experimental Neoplasia.” 
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IN VITRO ANTI-TUMOUR AND ANTI-ANGIOGENIC ACTIVITY OF 
AW464 (NSC 706704), A NOVEL QUINOL 
A Mukherjee*
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2, AD Westwell
2, MFG Stevens
2, J 
Carmichael
1 
Cancer Research UK Academic Unit of Oncology
1, University of 
Nottingham, Nottingham, UK, Cancer Research Laboratories
2, University of 
Nottingham, Nottingham, UK 
  
Introduction/Aims: AW464 (NSC 706704) is a novel benzothiazole 
substituted quinol compound with potent and selective activity concentrated 
in certain colon and renal cancer cell lines. The mechanism of action of 
AW464 however is not well understood. COMPARE analysis suggested 
possible interaction with thioredoxin/ thioredoxin reductase signalling. It is 
unknown whether it is likely to have any significant anti-angiogenic activity. 
In this study, the effects of AW464 were compared with those of Paclitaxel, 
which in addition to having direct tumour cell toxicity, also has a proven anti-
angiogenic action (Belotti D et al, 1996).  
Materials and Methods: In vitro experiments were performed on HT29, 
SW620 and SW480 colorectal cancer cell lines and on human umbilical vein 
endothelial cells (HUVEC). The effects of both drugs on cell growth were 
assessed by the MTS assay and growth curves. Effects on HUVEC 
differentiation were assessed by the Matrigel assay. In some experiments, 
HUVEC were exposed to tumour conditioned media to mimic the tumour 
environment. 
Results: The MTS assay and growth curve experiments demonstrated that 
AW464 exerted anti-proliferative effects on tumour cell lines as well as 
HUVEC at concentrations between 10
-5M and 10
-7M. This activity was 
comparable with Paclitaxel. HUVEC proliferation was significantly inhibited 
by exposure to tumour conditioned medium alone. Addition of AW464 
further suppressed proliferation slightly. Using the Matrigel assay, 
endothelial tube formation was partly inhibited within 24-48 hours by 
AW464 although this effect was less pronounced than with Paclitaxel. We 
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differentiation in addition to its tumour cell toxicity. 
Ref. Belotti D et al (1996) Clinical Cancer Research 2: 1843-1849 
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THE HORSERADISH PEROXIDASE/INDOLE-3-ACETIC ACID 
COMBINATION FOR ENZYME PRODRUG THERAPY: RROM IN 
VITRO TO IN VIVO. 
J. Tupper*, O. Greco, M.R.L. Stratford, G.M. Tozer, P. Wardman, G.U. 
Dachs. 
Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, 
Middlesex, HA6 2JR, UK. 
 
Cancer treatment is the main application of gene therapy, initially devised to 
correct inherited monogenic disorders. Gene directed enzyme prodrug 
therapy (GDEPT) involves the transfer of a gene encoding an enzyme to 
cells, and the subsequent administration of a prodrug, which is converted to a 
cytotoxin by the enzyme. Several GDEPT systems have been devised, 
including HSV thymidine kinase/gancyclovir and cytosine deaminase/5-
fluorocytosine. A recently developed system is the horseradish 
peroxidase/indole-3-acetic acid (HRP/IAA) combination (Greco et al., 2000, 
Cancer Gene Ther. 7, 1414). When expressed in mammalian cells in vitro, 
the plant enzyme HRP is able to convert IAA, a plant hormone, to a 
cytotoxin.  
In order to evaluate this combination further, we utilised the nasopharyngeal 
squamous cell carcinoma cell line FaDu, transfected with the HRP gene, in 
tissue culture, in tumour spheroids and in a xenograft tumour model. 
We show that HRP expression is able to selectively sensitise FaDu cell 
monolayers to IAA and 2 of its derivatives, 5bromoindole-3-acetic acid and 
1methylindole acetic acid, after 4 and 24 hour exposure. 5bromoindole-3-
acetic acid was active at lower concentrations than IAA, with 2-log cell kill at 
1 mM in HRP transfectants. 
As an intermediate between in vitro monolayers and in vivo experimental 
tumours, a 3-dimensional multitumour cell spheroidal model has been 
developed. IAA and its derivatives were also active in this more complex in 
vitro system. 
Xenografted tumours grown from HRP-transfected FaDu cells were shown to 
retain enzyme activity in vivo. Initial pharmacokinetic studies with a single 
bolus intraperitoneal injection of IAA indicate first order kinetics. With a 
non-toxic 250 mg/kg dose, plasma, liver and skeletal muscle concentrations 
peaked 10 minutes after administration. In the tumour, concentrations 
reached 1 mM, and remained above 0.5 mM for 50 minutes.  
These data provide promise for the ongoing evaluation of the HRP/IAA 
combination for GDEPT. 
This work was funded by Cancer Research UK. 
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DENDRITIC CELL IMMUNOTHERAPY FOR METASTATIC 
PROSTATE CANCER USING CRYOPRESERVED DENDRITIC 
CELLS PULSED WITH ALLOGENEIC TUMOUR LYSATE. 
John RJ*, Hutchinson JA, Pandha HS and Dalgleish AG. 
Department of Oncology, St George’s Hospital Medical School, Cranmer 
Terrace, London, SW17 ORE, United Kingdom 
 
Immunotherapy as a treatment modality for hormone-refractory prostate 
cancer (HRPC) has shown promise in recent trials using whole cell vaccines 
and dendritic cell (DC) approaches. However, DC-based strategies have been 
limited by the need for repeated venesection or leukapheresis to provide 
sequential supplies of DCs for modification and vaccination. We have 
developed a method of culturing then cryopreserving monocyte-derived DCs 
after pulsing with irradiated allogeneic prostate cancer cell lysate. The freeze-
thaw process resulted in minimal loss of cells, increased DC maturation and 
thus enhanced antigen-presenting capability. This method has provided 
numerous identical aliquots of DCs; one aliquot is thawed, tested for 
phenotype, function and microbial contamination prior to administration. In 
this way we ensured patients received identical sequential vaccines. We have 
completed a phase I/II, local research ethics committee approved clinical trial 
of 14 patients with metastatic HRPC who received 1 x 10
6 DCs intradermally 
or intranodally at 2 weekly intervals for 3 months then monthly. Keyhole 
limpet haemocyanin (KLH) was used as the adjuvant. This protocol was safe 
and non-toxic with only 2 reports of slight fever. Initial results indicate a PSA 
response in 4 patients, 2 with an arrest in PSA levels over 4 months and 2 
showing reduction in PSA velocity over the same time period. All patients 
showed a positive delayed-type hypersensitivity test (DTH) prior to 
commencing treatment confirming their immunocompetence. We intend to 
assess response to vaccine clinically, radiologically, DTH response to 
intradermal injection of the tumour lysate, ELISPOT, cell-specific cytokine 
production using CBA array and proliferative lymphocyte responses to 
vaccine DCs or recall antigens.  
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VACCINATION WITH NAKED DNA ENCODING MURINE FLT3 
LIGAND DOES NOT CONFURE TUMOUR PROTECTION SEEN 
WITH RECOMBINANT PROTEIN. 
Matthew Turner*, Hardev Pandha and Angus G. Dalgleish 
Division of Oncology, St George's Hospital Medical School, Tooting, 
London, SW17 ORE, UK 
 
Flt3 ligand is a novel haematopoietic growth factor.  Its administration has 
been shown to increase dendritic cell and natural killer cell numbers and 
activity in vivo by activating and expanding Dendritic Cell and Natural Killer 
cell progenitors.  Previous studies used the recombinant protein have shown 
increased tumour rejection and survival in melanoma and lymphoma. 
However, this is of limited availability and high cost.  The use of 
Polynucleotide DNA using cytokine cDNA cloned into eukaryotic expression 
vectors has shown efficacy as a vaccine in infectious disease and cancer 
models.  Plasmid DNA expressing the extracellular domain of murine flt3 
ligand was produced using a standard DNA extraction kit. Its expression was 
confirmed by COS cells transfection. We studied the effect of vaccinating 
with flt3 ligand alone, or in combination with the melanoma antigens TRP1 
and TRP2.  The cytokine GMCSF was also included in the vaccination 
protocol.  We were unable to reproduce the results demonstrated using the 
recombinant flt3 ligand with no significant survival or immune responces. 
Combination of flt3 ligand with antigen did confer a slight protection. 
GMCSF did produce a survival advantage that appeared independent of 
tumour antigen. 
We are unaware of any published studies using flt3 ligand as a DNA vaccine 
prior to this.   
All in vivo work was carried out in strict accordance with Home Office and 
Institutional Guidelines 
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STRATEGIES TO IMPROVE MURINE MELANOMA ALLOGENEIC 
VACCINE USING CYTOKINE GENE TRANSFECTION 
Ward, S.J.*
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2, Birchall, L.J.
2, Desel, C.
1, Russell, N.
1, Whelan, 
M.
1, Dalgleish, A.G.
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Onyvax Ltd. 
1 and Dept. of Oncology 
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Syngeneic tumour cell vaccines are difficult to produce, due to the inherent 
problems associated with bespoke vaccine production. Stable, well 
characterised allogeneic tumour cell vaccines containing cross-reactive 
tumour antigens circumvent these problems, and are an attractive proposition. 
Using the B16-F10 murine melanoma system, we have shown vaccination 
with irradiated, allogeneic tumour cells to protect from challenge with live, 
syngeneic tumour. The introduction of cytokine encoding sequences into 
syngeneic vaccine cells has been shown to increase vaccine efficacy by 
several groups (Dranoff, Jaffee, Lazenby et al., 1993, PNAS USA, 90:3539). 
In this study, we introduced the following murine cytokine sequences into 
B16-F10 cells using the pLXIN (Clontech) retroviral system; GM-CSF, IL-2, 
IL-4, IL-7. Single clones were selected, rendered replication incompetent by 
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(C3H/HeN) female mice sub cutaneously. Following 2 doses of vaccine, 
mice were challenged on the opposing flank with a tumourigenic dose of 
syngeneic tumour. Immunisation with allogeneic vaccine expressing cytokine 
did not confer any real survival benefit when compared to the wild type 
vaccine. However, transfection with IL-2 did produce a small, but significant, 
increase in survival time. In contrast, only IL-4 transfection increased the 
efficacy of wild type vaccine within the syngeneic mice. Splenocytes from 
allogeneic immunised mice were able to produce significant levels of CTL 
killing specific for the syngeneic tumour challenge cells. In addition, 
cytokines such as TNF-alpha, IFN-gamma, IL-2 and IL-5 were also induced 
by these splenocytes following in vitro incubation with both syngeneic whole 
tumour cells and lysate. Thus, vaccination with allogeneic cells induces a 
cellular immune response which can cross-react and protect against challenge 
with syngeneic tumour. The potency of the host’s anti-allogeneic response 
appears to be such that the introduction of additional cytokine genes into the 
vaccine does not readily improve vaccine efficacy. 
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DETECTION OF THYMIDYLATE SYNTHASE (TS) INHIBITION 
K.Yau, P. Price, & E.O. Aboagye*, Cancer Research UK PET Oncology 
Group, Imperial College School of Medicine, MRC Cylotron Unit, 
Hammersmith Hospital, Du Cane Road, London W12 0NN. 
 
The aim of this study is to validate the use of radiolabelled thymidine 
([
3H]TdR) uptake as a measure of TS inhibition.  The working hypothesis is 
that TS inhibition causes a depletion in thymidine monophosphate and to 
overcome this blockade, cells undergoing DNA synthesis will increase the 
amount of labelled thymidine taken up via the salvage pathway. 
RIF-1 cells growing in culture showed an increase in [
3H]TdR
 uptake at 0, 2 
and 6 h after a 2-h treatment with 5-fluorouracil (5-FU; 1-100 g/ml).  A 
decrease in [
3H]TdR
 uptake was observed at 24 and 48 h.  Both effects were 
dose dependent but whereas the maximum increase in [
3H]TdR
 was only 25 ± 
2% of controls, the decrease in [
3H]TdR uptake at 48 h for instance was 
>95% at high concentrations.  A similar effect was seen in HT29 cells 
(slower growing) treated with 5-FU, although the decrease in [
3H]TdR at the 
latter time points was less marked.  In contrast, treatment of the cells with 
cisplatin (non-TS inhibitor; negative control) led to a decrease in [
3H]TdR 
uptake at 2, 6, 24 and 48 h.  To further confirm that the early increase in 
[
3H]TdR  uptake was dependent on TS inhibition, similar studies with the 
non-classical TS inhibitor AG337 were performed. In RIF-1 cells, AG337 
treatment (0.05-5 g/ml; continuous exposure) resulted in a large increase in 
[
3H]TdR
 uptake (up to 152 ± 5% of controls at 2 h).  The increase in [
3H]TdR 
peaked at 2 h, was still high at 6 h but as with 5-FU, decreased at 24 and 48 
h.  In all cases MTT assays were performed in parallel with the [
3H]TdR 
uptake studies.  These studies showed that the early increase in [
3H]TdR 
uptake observed was not due to an increase in viable cell number.  Although 
a decrease in formazan production was observed in all cases where there was 
a decrease in [
3H]TdR
  uptake, this was less pronounced compared to the 
decrease in [
3H]TdR uptake.  This implies that the decrease in [
3H]TdR 
uptake at the latter time points could be explained in part by a decrease in cell 
number.  
The above studies support the clinical use of [
11C]thymidine as a non-
invasive positron emission tomography probe for imaging TS inhibition in 
patients and indicate the appropriate timing for such studies.  Future 
experiments will assess whether the changes in [
3H]TdR uptake correlate 
with direct measures of TS inhibition. 
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CONCOMITANT HER2 AND FARNESYLTRANSFERASE 
BLOCKADE BY R115777 AND TRASTUZUMAB IN PATIENTS 
WITH ADVANCED CANCER. 
JS de Bono*, G. Schwartz, LA Hammond, L Smith, A. Patnaik, K. Berg, E. 
Izbicka, EK Rowinsky, AW Tolcher. Institute for Drug Development, 7979 
Wurzbach Road, Suite 400, Zeller Building, Cancer Therapy and Research 
Center, University of Texas Health Science Center, and Brooke Army 
Medical Center, San Antonio, TX. 
Introduction:  The recombinant human monoclonal antibody trastuzumab 
targets cellular proliferation by blocking HER2 signaling. However the 
majority of patients who overexpress HER2 fail to respond to single agent 
trastuzumab. Farnesyltransferase regulates the post-translational modification 
of a number of important proteins including the cell signaling protein ras. 
Farnesyltransferase inhibition can thereby block ras signaling. Concurrent 
farnesyltransferase and HER2 blockade result in synergistic antitumor 
activity in HER2 positive cell lines. R115777 is a potent, selective and non-
peptidomimetic inhibitor of farnesyltransferase that can inhibit the growth of 
H-, K-, and N-ras transformed as well as wild-type ras xenograft tumors. It 
has single agent clinical activity in breast cancer. Methods: A phase I study 
in patients with HER2 positive disease of oral R115777 and trastuzumab was 
pursued. Trastuzumab doses were fixed at 4 mg/kg IV day 1, then 2 mg/kg 
IV weekly. R115777 dose levels studied were 200 mg, 300 mg, and 400-mg 
po bid for 21-days every 28 days. Results: Twenty-one patients (8 breast, 5 
NSCLC, 4 colon, and 1 each of ovary, pancreas and leiomyosarcoma) have 
received 78 courses (range: 1-13; median: 4) of R115777 and trastuzumab. 
Protracted grade 4 neutropenia lasting more than 5 days, fever, and grade 3 
thrombocytopenia were dose limiting at an R115777 dose of 400 mg bid. 
Non-hematologic toxicities have been mild and include nausea/vomiting), 
headache and fatigue. No clinically significant decrements in LV ejection 
fraction have been observed. One patient with colorectal cancer has had a 
partial response. Overall 4 patients have remained on study for more than 8 
months (2 colorectal, 1 breast, 1 leiomyosarcoma). Surrogate studies in 
peripheral blood mononuclear cells have demonstrated inhibition of hDJ 
chaperone protein farnesylation at all R115777 doses evaluated. R115777 
and trastuzumab can be safely administered at full doses for both agents. 
Conclusion: This combined signal transduction inhibition approach warrants 
further investigation and a Phase II evaluation of this combination in HER2 
positive breast cancer patients is now underway.  
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PHASE I AND PHARMACOKINETIC (PK) STUDY OF THE 
EPOTHILONE-B ANALOGUE BMS-247550 BY A CONTINUOUS 
WEEKLY SCHEDULE.  
JS de Bono*, D Hao, LA. Hammond, AW. Tolcher, K. Berg, A Bass, T. 
Mays, L Smith, R Drengler, EK Rowinsky. Institute for Drug Development, 
7979 Wurzbach Road, Suite 400, Zeller Building, Cancer Therapy and 
Research Center, University of Texas Health Science Center, San Antonio, 
Texas. 
 
Introduction: Epothilone B is a non-taxane microtubule-targeting agent
 that 
induces tubulin polymerization and stabilizes microtubules.
  Similar to 
paclitaxel epothilone B blocks the
 cell cycle at the G2-M transition, thereby 
inducing apoptosis. Epothilone B and its lactam analogue BMS-247550 are 
active against paclitaxel-resistant tumor
  cells.  Methods:  Since weekly 
administration of other anti-microtubule agents has afforded a favorable 
toxicity profile BMS-247550 was administered continuously once weekly by  
a 60-minute intravenous infusion utilizing a 28-day regimen. Toxicity 
endpoints were sought separately in heavily (HP) and minimally pretreated 
(MP) patients. Results: Twenty patients (M:F=9:11) with a median age of 52 
years and a median ECOG PS of 1 (6 colorectal; 3 ovarian; 3 NSCLC; 2 each 
of prostate, melanoma and breast; and 1 each uterus and cervix) have 
received 49 four-week courses (range 1 to 5; median 2) of BMS-247550. 
Dose-limiting toxicities include grade 3 fatigue in 1 HP pt at 20 mg/m
2, 
protracted grade 4 neutropenia (>5 days) in 2 HP patients at 30 mg/m
2 and 
neutropenic sepsis in 1 MP patient at 30mg/m
2. Neutropenia also precluded 
weekly treatment on-time in 2 of 3 MP patients at 30 mg/m
2 during course 1. 
One patient with hormone-, mitoxantrone- and paclitaxel-refractory prostate 
carcinoma had a greater than 50% PSA decrement (from 5100 to 810) with 
complete resolution of his tumor related bony pain. This patient developed 
grade 3 peripheral neuropathy and grade 2 fluid retention necessitating his 
withdrawal from the study after 6 months of treatment. A minor response was 
observed in a patient with melanoma, and tumor marker decrements were 
noted in 3 patients with taxane-refractory ovarian carcinoma.  Neuropathy, 
assessed clinically, by nylon monofilament testing and nerve conduction 
studies, was observed in 6 patients (NCI-CTC grade 1 or 2 in 5; grade 3 in 1) 
and seen mainly at doses above 20 mg/m
2 with repeated dosing. All other 
drug-related toxicities have been mild  to moderate ( grade 2) including 
anemia, fatigue, myalgias, arthralgias, alopecia, anorexia, nausea, diarrhea, 
vomiting and thrombocytopenia. PK studies indicate dose-proportional 
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parameters: t1/2=50.442.7 hour; Vss=795.4331.5 L/m
2; Cl=23.915.2 
L/hr/m
2. The erythromycin breath test did not predict drug clearance. Accrual 
continues at 25 mg/m
2/wk (HP) and 30 mg/m
2/wk (MP) to define safe dose 
schedules for MP and HP patients.  Conclusion: This weekly schedule of 
BMS247,550 has clinical anticancer activity and warrants broad disease-
oriented testing in phase II studies 
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METABOLICALLY ACTIVE CYTOCHROME P450 CYP1B1 IN 
SOLID TUMOURS: A NOVEL TARGET FOR 
CHEMOTHERAPEUTIC INTERVENTION. 
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2, Graeme I. Murray
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Department of Pathology, 
2Department of Molecular and Cellular Biology, 
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Cytochrome P450 CYP1B1 is a member of a superfamily of haemoproteins 
which are central to the oxidative metabolism of a wide variety of 
endogenous and exogenous compounds.  Several of these enzymes have an 
established role in the metabolic bio-transformation of a variety of anti-
cancer drugs.  We have previously shown that CYP1B1 is a tumour-specific 
form of cytochrome P450 highly expressed in a variety of malignant tumours 
localised specifically to tumour cells
1.  In contrast CYP1B1 protein is un-
detectable in corresponding normal tissue.  Recently we have identified 
several anti-cancer drugs that are substrates for CYP1B1
2.  Moreover, our in 
vitro studies have shown that the presence of CYP1B1 reduces the efficacy of 
some of these neoplastic agents
3.  Cytochrome P450 enzymes require the 
presence of cytochrome P450 reductase (CPR) for optimal metabolic activity.  
Since CYP1B1 metabolises anti-cancer drugs in tumour cells it is important 
to determine the level of active CYP1B1 and CPR in tumours.  In this study 
we demonstrated both CYP1B1 and CPR activity in the microsomal fraction 
of ovarian (n=9) and kidney tumours (n=24).  The Ortho-deethylation of 
ethoxyresorufin to resorufin was used to measure CYP1B1 activity.  We have 
found CYP1B1 activity in the 100,00g fraction in both ovarian and kidney 
tumours (100-800 fmol/min/mg of protein).  Co-incubation with the CYP1B1 
inhibitor alpha-naphthoflavone inhibited this activity.  No CYP1B1 activity 
was observed in any of the normal kidney samples examined (n=8).  CPR 
activity was determined spectrophotometrically by measuring the reduction 
of cytochrome c at 550nM.  CPR activity was detected in all normal and 
tumour samples (0.04-3nmol/min/mg protein).  The presence of CYP1B1 
which is capable of metabolising anti-cancer drugs and which is active only 
in tumour cells highlights a novel target for chemotherapeutic intervention.  
References 
1. Murray GI, Melvin WT, Greenlee WF, Burke MD. 2001 Annu Rev 
Pharmacol Toxicol 41: 297. 
2. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. 2001 J 
Pharmacol Exp Ther 296: 537. 
3. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, 
Murray GI. 2001 Biochem Pharmacol 62: 207. 
Acknowledgement: This research was funded by Cancer Research UK and 
the Gray Fund. 
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Pharmacokinetic analysis is often a bottleneck in the drug discovery process.  
The aim of this study was to evaluate cassette dosing, the simultaneous 
administration of several compounds to a single animal, and in vitro 
metabolic stability screening as methods to predict the pharmacokinetics of a 
series of novel DNA-dependent protein kinase (DNA-PK) inhibitors in high 
throughput.  DNA-PK is involved in the repair of double strand breaks, thus 
inhibition of this enzyme may potentiate the effects of radiotherapy or 
chemotherapy by DNA-damaging agents.  NU7053, NU7059, NU7062, 
NU7119 and NU7163 were administered intravenously to Balb C
- mice alone 
at 5mg/kg and in combination at 1mg/kg each.  Mouse liver microsomal 
incubations of the five compounds were carried out at a concentration of 
10M for 20 minutes.  Plasma and microsomal concentrations were 
measured by HPLC-MS/MS with multiple reaction monitoring.   
Pharmacokinetic parameters were evaluated by non-compartmental analysis.  
The compounds displayed a linear increase in maximum concentration 
(Cmax) and area under the curve (AUC) with a 5-fold increase in dose from 
1mg/kg cassette administration to 5mg/kg single administration.  The 
clearance and half-lives of the compounds were similar following cassette 
and single dosing.  For example, the clearance and half-life of NU7059 
following cassette and single dosing was 0.091L/hr and 0.17hr, and 
0.081L/hr and 0.16hr respectively.  The compound which showed the lowest 
clearance (0.091L/hr), NU7059, also showed the lowest extent of metabolism 
(28%).  Conversely, NU7053 displayed the highest clearance (0.46L/hr) and 
metabolism (98%) of the five compounds.  The rank order of the compounds 
from lowest to highest clearance was similar whether they were dosed as 
single agents (NU7059 > NU7163 > NU7119 > NU7062 > NU7053) or in 
combination (NU7059 > NU7119 > NU7163 > NU7062 > NU7053).  This 
ranking was maintained in terms of metabolic stability (NU7059 > NU7119 > 
NU7163 > NU7062 > NU7053).  In conclusion, both in vivo cassette dosing 
and in vitro metabolic stability screening are suitable methods to evaluate the 
pharmacokinetics of novel DNA-PK inhibitors.  These methods will be used 
to assess a larger number of compounds from this series in order to increase 
throughput whilst reducing the number of animals used. 
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Aims  Cisplatin-DNA adducts, formed in inherently drug resistant 
adenocarcinoma lung cancer cell line (Mor), and drug sensitive small cell 
lung cancer line (H69) appear to be markedly different in structure as 
indicated by differences in immunoreactivity using CP9/19 monoclonal 
antibody (1). The antibody does not recognise Pt-pApG adducts and the 
initial aim of the present work was to test the hypothesis that the difference 
between the cell lines was in the ratio of major DNA adducts.  
Methods The Pt-DNA adducts present in DNA extracted from the two cell 
lines exposed to cisplatin were analysed, using anion exchange 
chromatography (Mono Q), after enzymatic digestion of the Pt-DNA (2). 
Fractions were collected every 30 seconds, and the total Pt in each fraction 
was determined, using the sensitive Inductively Coupled Plasma Mass 
Spectrometry (ICP-MS) technique. This permits analysis of DNA containing 
relatively low adduct levels (3). 
Results The high sensitivity of ICP-MS permitted, for the first time, direct 
analysis of Pt in chromatography fractions from the analysis of DNA 
extracted from drug treated cells. The ratios of Pt-pGpG to Pt-pApG cross-
links were similar in both lines and were consistent with established data (2). 
However, additional Pt containing peaks were detected compared to those 
resulting from analysis of reaction products of cisplatin with purified DNA. 
Conclusion The difference in immunoreactivity, in Pt-DNA adducts of the 
two cell lines, was not due to differences in relative levels of the major 
adducts. The additional types of adducts formed in cells do not appear to 
account for the differences between the cell lines but these need further 
investigation. The base sequence, where the platinum binds to the DNA is 
currently being investigated, as these appear to affect the immunoreactivity of 
Pt-DNA adducts.  
1) Tilby et al. 1991, Cancer Res. 51: 123.  
2) Fichtinger-Schepman et al. 1985, Biochem. 24: 707. 
3) Azim-Araghi et al. 2001, In plasma source mass spectroscopy, by Holland 
& Tanner, 412.  
This research is supported by Cancer Research UK. 
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The effect of the anti-vascular agent combretastatin A-4 phosphate (CA4P) 
on tumour biology is not fully understood. It has previously been reported 
that CA4P, a tubulin binding agent, causes vascular shutdown and necrosis in 
tumours in vivo. To further analyse the role of CA4P, we are using a Zeiss 
microscope with motorised stage and accompanying KS300 image analysis 
software, to investigate its effect on selected tumour parameters over time 
using a human colorectal xenograft in nude mice. These include vascular 
distribution (CD31), perfusion (Hoechst 33342), hypoxia (Pimonidazole), 
and cell proliferation (BrdU). Mice received either no treatment or a single IP 
dose of CA4P (200 mg/kg), the latter being sacrificed at either 1 or 24 hours 
after treatment. Quantitative analysis of relative changes in these parameters 
following therapy will be discussed. 
Control tumours: CD31 and Hoechst staining demonstrated perfused blood 
vessels throughout the whole of the tumour. Similarly, BrdU positive cells 
were also found in both central and peripheral parts of the tumour. In 
contrast, pimonidazole staining revealed some areas of hypoxia that tended to 
be distant from blood vessels and/or surrounding necrosis.  
Treated tumours: Vascular shutdown studies demonstrated that treatment 
with a single dose of CA4P resulted in almost complete vascular shutdown 1 
hour after treatment. Simultaneous fluorescent staining of both Hoechst and 
CD31 revealed that although blood vessels were distributed throughout the 
whole of the tumour, perfused vessels were predominantly in the outer rim 
with only a few found in the central part of the tumour. Interestingly, BrdU 
staining revealed that proliferation corresponded to the well perfused outer 
rim, while only a few nests of cells surrounding blood vessels within the 
poorly perfused central part of the tumour stained positive for BrdU. These 
data indicate that a 1 hour treatment with a single dose of CA4P resulted in 
both vascular shutdown as well as a block in proliferation. Pimonidazole 
staining, on the other hand, revealed that at this time point, hypoxia was most 
commonly found in the tumour centre with little or no staining at the outer 
rim of the tumour. At 24 hours after treatment, when most of the tumour was 
necrotic, both perfusion and proliferation were restricted to the viable region 
at the edge of the tumour. Furthermore, pimonidazole staining was also seen 
in the viable rim, demonstrating hypoxic cells bordering regions of tumour 
necrosis.  
Taken together, the data in this study provide further insight into the 
mechanisms by which CA4P may exert its effects on tumour cells.  
Supported by the Association for International Cancer Research, Cancer 
Research UK, and Trusthouse Charitable Foundation. CA4P was kindly 
supplied by OXIGENE.  
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Curcumin, the major yellow pigment extracted from the spice turmeric, 
possesses a broad spectrum of chemopreventive efficacy.  It has been shown 
to prevent carcinogen-induced malignancies and premalignancies in rodents.  
It is also active in the Min/+ mouse, a genetic model of human hereditary 
familial adenomatous polyposis.  The aim of this study was to determine an 
efficacious dose of curcumin and an optimal time period of administration in 
the Min/+ mouse.  We also determined curcumin levels by HPLC analysis 
commensurate with potential efficacy.  C57BL/6J Min/+ mice were divided 
into 5 groups (n=10-14 in each).  Control mice were kept on a high-protein 
(RM3) diet, to reflect western-style human diets.  Mice received curcumin 
(0.2% in RM3) for the following time periods: i. perinatally and up to day 30, 
ii. from day 30 to day 75, iii. from day 75 to day 120, iv. from day 30 to day 
120.  At 120 days the study was terminated, and small intestinal adenomas 
were scored.  To assess the effect of the high protein basal diet on its own, 
C57BL/6J Min/+ mice received RM3 or a standard AIN76A diet from day 30 
to day 120.  Curcumin administered from day 30 to day 120 significantly 
reduced small intestinal tumour formation by 39% compared to controls 
(p<0.05), whilst administration for shorter periods of time failed to alter 
tumour burden.  The steady state level of curcumin in intestinal mucosa tissue 
of mice on 0.2% curcumin was 11023 nmoles/g.  Comparison of the basal 
diets showed that tumour burden is significantly lower when mice are fed a 
low-protein (AIN76A) diet, decreasing total intestinal adenoma number from 
1108 to 613.3 (p< 0.05;  SEM).  The results highlight the potential 
chemopreventive activities of a low-protein diet and of curcumin, and hint at 
the possible clinical relevance of curcumin as a colorectal cancer 
chemopreventive agent in humans. 
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NU:UB 31 is a spacer-linked anthraquinone-L-proline conjugate which 
belongs to a series of compounds designed to inhibit DNA topoisomerase 
enzymes. Unlike most topoisomerase inhibitors in current clinical use, 
NU:UB 31 has been shown in vitro to be a dual inhibitor of DNA 
topoisomerase I and II
1. The aim of this work was to study the in vitro and in 
vivo antitumour activity and pharmacokinetics of the compound. IC50 values 
for the compound calculated against MAC 15A (murine adenocarcinoma) 
cells using a MTT assay were 5, 8, and 38 M for 1, 24 and 96-hour 
exposures respectively. Previous work has shown that treatment with NU:UB 
31 at its maximum tolerated dose of 100 mg kg
-1 led to a significant delay in 
tumour growth (P<0.01)
2. The activity of doses below the MTD was assessed 
to look at the therapeutic range of the compound. NU:UB 31 was 
administered to NMRI mice bearing subcutaneous MAC 15A tumours i.p. (in 
DMSO/oil) at single doses of 67, and 33 mg kg
-1 and tumours were measured 
daily. The growth delay for each dose was 4.3, and 3.2 days respectively. In 
both cases, treatment resulted in a statistically significant delay in tumour 
growth (p<0.01) compared to controls.  
A method was developed to detect and analyse NU:UB 31 in biological 
samples using LC-MS. Initial work assessed the stability of the compound in 
vitro with NU:UB 31 having t1/2 values of 75.1 and 25.7 hours in tissue 
culture medium and whole murine blood respectively at 37
oC. The compound 
was very stable in murine plasma with t1/2 >100 hours. Pharmacokinetic 
analysis of NU:UB 31 in vivo was assessed in MAC 15A tumour bearing 
mice. NU:UB 31 was given i.p. at 100mgkg
-1 and plasma and tumour levels 
monitored over an 8 hour period. Drug concentration peaked in the plasma 
after 30 minutes (Cmax = 12 g ml
-1) with a t1/2 value of 2.2 hours and AUC of 
44.5  g h ml
-1. Peak tumour concentrations exceeded those seen in the 
plasma by approximately 3-fold peaking at 2 hours (Cmax = 39.5 g g
-1) with 
a t1/2 of 6 hours and AUC of 371 g h g
-1 (8-fold greater than plasma). IC50 
values for the compound in vitro were converted to CxT values (taking into 
account the stability of the drug in tissue culture medium) giving values of 
18.8, 82, and 176.2g h ml
-1 for 1, 24 and 96 hour exposures respectively. 
The concentration of NU:UB 31 measured in MAC 15A tumours in vivo 
therefore exceeds those of the in vitro IC50 values. The concentration of 
NU:UB 31 in tumours and the long half life may go some way to explaining 
the good anti-tumour activity seen against MAC 15A tumours. 
Refs: 
1 Gilmour et al, Annals of Oncology 9(S2): 62 (1998). 
2 Mincher et al, British Journal of Cancer 80(S2), P87: 50 (1999). 
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formation of damage in genomic DNA. In addition to ‘simple’ individual 
lesions, a number of agents, such as ionising radiation and certain 
chemotherapeutic drugs, are proposed to generate ‘complex’ multiply 
damaged sites (MDS) where several moieties in a local region of the DNA 
(~10 bp) are damaged. Such complex lesions are proposed to be of 
heightened biological significance due to the greater challenge they present 
repair systems. 
Given the significance and potential for MDS to occur, it is desirable to have 
analytical techniques that will allow their direct detection. However, other 
than indirect measures, such as the measurement of immediate and latent 
DNA double-strand breaks, there are few analytical techniques that allow 
direct detection of MDS in DNA. 
In the present study we demonstrate the potential of protocols incorporating 
an exonucleolytic snake venom phosphodiesterase (SVPD, phosphodiesterase 
I) digestion stage to permit the direct detection of certain tandem damage, in 
which two lesions are immediately adjacent to each other on the same DNA 
strand. 
A series of oligonucleotides containing either single or pairs of abasic 
tetrahydrofuran moieties (F) or oxidative thymine glycol lesions (T
g) were 
prepared and digested with SVPD (in the presence of DNase I and alkaline 
phosphatase (AP)). The digests were then subject to HPLC analysis and the 
isolated products examined by either 
32P-end-labelling or electrospray mass 
spectrometry. In addition, a series of oligonucleotides containing either single 
or pairs of alkylative methylphosphotriester adducts (Me-PTE) were digested 
with SVPD + NP1 (+DNase I/AP) and directly examined by a 
32P-end-
labelling protocol specific for phosphotriester adducts
1. The unambiguous 
observation of SVPD-resistant ‘trimer’ species in the digests of 
oligonucleotides containing adjacent F, T
g and Me-PTE demonstrates that the 
SVPD digestion strategy retains some MDS structures and is capable of 
allowing direct detection of certain tandem damage. Furthermore, in studies 
to determine the specificity of SVPD in dealing with pairs of lesions on the 
same strand, it was found mandatory to have the two lesions immediately 
adjacent to each other in order to generate the trimer species; pairs of lesions 
separated by as few as one or two normal nucleotides behave principally as 
single lesions towards SVPD. Although the 5’-phosphodiester linkage 
adjacent to tandem lesions was highly refractory to SVPD digestion, 
comparison of peak ratios between SVPD digested oligonucleotides 
containing single lesions with those containing tandem lesions, following 
HPLC analysis, suggest that SVPD hydrolysis of the 5’-phosphodiester 
linkage adjacent to some single lesions can occur. 
1. Guichard  et. al. (2000) Cancer Research 60, 1276. 
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Introduction 
Ewing’s sarcoma and primitive neuroectodermal tumour are members of the 
Ewing’s family of tumours. This is consistently associated with chromosomal 
translocation and functional fusion of the EWS gene to transcription factor 
genes, such as Fli1 (95% of cases). The resulting chimaeric proteins are 
believed to contribute to tumour biology by aberrant regulation of gene 
expression altering controls of cell cycle regulation. These tumour-specific 
molecular rearrangements are useful as potential therapeutic targets. For this 
to be effective a detailed understanding of the difference between EWS-Fli1 
protein at the level of gene expression is required. 
Methods 
Fli1 and EWS-Fli1 were cloned into the pET32a vector system. Expression 
of protein was achieved by growth at 37C until an A600 of 0.3 was achieved, 
at which stage the bacteria were induced with 0.1mM IPTG and grown 
overnight at 25C. Cells were harvested, sonicated and pelleted. The 
supernatant was collected as soluble protein. 
Purification involved incubation of nickel NTA-agarose with protein sample 
for 3 hours. Sample was eluted with 1M Imidazole elution buffer. 
Sequencing was conducted with the use of ABI sequencing manual. 
Results 
We have demonstrated expression of Fli1 and EWS-Fli1 proteins by the use 
of western blot analysis. We have optimised soluble expression of the Fli1 
and EWS-Fli1 proteins. 90% purity has been achieved, with the use of 
affinity chromatography.  
Following optimisation of purification, achieved by Ion exchange 
chromatography, future work would entail analysis of structural similarities 
between Fli1 and EWS-Fli1.  
Conclusion 
We have managed to achieve high expression of soluble Fli1 and EWS-Fli1. 
These proteins can therefore be used for detailed three dimensional structural 
analysis to elucidate differences in DNA:protein binding between the two 
proteins thus allowing the development of novel therapeutic strategies.  
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Background The tumour suppressor p53 is a stress-inducible transcription 
factor which modulates the expression of genes involved in cell growth or 
apoptosis.  This damage-inducible characteristic of the p53 pathway is linked 
to the death induced in tumour cells after being exposed to chemotherapeutic 
drugs or radiation. In order to improve the efficiency of anti-cancer drugs as 
single agents or in combination, p53 pathway modulation is an obvious 
choice. In this study we investigated the effects of the anthracycline 
doxorubicin and the vinca alkaloid vinorelbine on the induction and 
phosphorylation status of p53 in the breast cancer cell line MCF7. 
Materials and Methods MCF7 cells were grown in DMEM containing 10% 
FCS and 1% P/S at 37
oC and 5% CO2.  At 70% confluence, medium 
containing 50 nM doxorubicin or 5 nM Vinorelbine as single agents or a 
combination of both drugs was added. After 4 and 24 h treatment the cells 
were harvested by scraping and lysates produced using urea buffer. p53 
expression was determined using the antibody DO-12 (specific for p53 core 
domain). The phosphorylation status at Ser15, Thr18, Ser20 and Ser315 was 
investigated using phospho-specific monoclonal antibodies. 
Results  Induction of p53 expression was observed after treatment with 
doxorubicin (single or combination) but not with vinorelbine. A key 
regulatory step in the control of p53 function implicates the mdm2 ubiquitin-
dependent degradation pathway. Ser15 phosphorylation is thought to 
simultaneously reduce mdm2 binding (and subsequent p53 degradation) and 
promote interaction of p53 with components of the transcriptional machinery. 
Ser15 phosphorylation was observed after doxorubicin but not vinorelbine 
treatment. It has been shown that phosphorylation of p53 at Ser315 primes 
and stimulates its DNA binding function in vitro. Doxorubicin treatment but 
not vinorelbine resulted in phosphorylation of Ser315. However, when both 
drugs were added together a decrease in Ser315 phosphorylation was 
observed compared to the results obtained with addition of doxorubicin on its 
own.  
Conclusion This data suggest that chemotherapeutic drug interactions may 
affect doxorubicin anticancer activity on the p53 pathway. 
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85-90% of cancers express the enzyme telomerase which is contrastingly 
absent in benign tumours and most normal somatic cells: telomerase has 
therefore become a target for cancer treatment.  Small molecules capable of 
stabilising the G-quadruplex structure thought to exist in telomeric repeat 
sequences, inhibit telomerase.  RHPS4 inhibits 50% of telomerase activity at 
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